FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100791732> ?p ?o ?g. }

• W2100791732 endingPage "A523" @default.
• W2100791732 startingPage "A523" @default.
• W2100791732 abstract "To evaluate the cost-effectiveness of apixaban in the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) from a French payer perspective. A Markov model was developed in accordance to the new French guidelines of the Commission for Economic Evaluation and Public Health (CEESP) that also recommends applying efficiency frontier. A hypothetical cohort of patients with NVAF, 70 years old eligible for stroke preventive treatment (CHADS2≥1) was simulated over lifetime. Clinical events modeled included strokes, systemic embolism, intracranial hemorrhage, other major bleeds, clinically relevant non-major bleeds and myocardial infarction. Treatment efficacy and bleeding data was obtained from ARISTOTLE. Efficacy data are from published indirect comparisons. Acute medical costs of stroke and hemorrhage were obtained from a dedicated analysis of the French national hospitalization database (PMSI). Long-term medical costs and utility data were derived from the literature. Univariate and probabilistic sensitivity analyses (PSA) were also performed to assess the robustness of the model projections. Three strategies were strictly dominated: aspirin, dabigatran 110mg, and dabigatran in sequential dosages. Two others were extendidly dominated: rivaroxaban and dabigatran 150mg. The efficiency frontier was constructed by connecting the remaining strategies: warfarin and apixaban. Apixaban resulted in an incremental additional cost of 2,870€ and an incremental QALY of 0.189, corresponding to an ICER of 15,157€/QALY versus warfarin. The PSA indicated that the probabilities for apixaban being cost-effective versus warfarin were respectively 80% and 90% at the informal willing-to-pay thresholds of 30,000€ and 50,000€. Sensitivity analysis identified stroke risk with apixaban and intracranial hemorrhage risk with warfarin as the variables most influencing the results. Apixaban may be the most economically efficient alternative to warfarin in NVAF patients eligible for stroke prevention in France. All other strategies are dominated. However, uncertainty surrounding these results should be investigated through real life data." @default.
• W2100791732 created "2016-06-24" @default.
• W2100791732 creator A5042408270 @default.
• W2100791732 creator A5045519884 @default.
• W2100791732 creator A5060092467 @default.
• W2100791732 creator A5060734176 @default.
• W2100791732 creator A5064805536 @default.
• W2100791732 creator A5065617907 @default.
• W2100791732 creator A5080756848 @default.
• W2100791732 date "2013-11-01" @default.
• W2100791732 modified "2023-10-16" @default.
• W2100791732 title "Application of New French Guidelines for Economic Evaluations: A Cost-Effectiveness Analysis of Apixaban in Patients with Non-Valvular Atrial Fibrillation in France" @default.
• W2100791732 doi "https://doi.org/10.1016/j.jval.2013.08.1266" @default.
• W2100791732 hasPublicationYear "2013" @default.
• W2100791732 type Work @default.
• W2100791732 sameAs 2100791732 @default.
• W2100791732 citedByCount "2" @default.
• W2100791732 countsByYear W21007917322013 @default.
• W2100791732 countsByYear W21007917322014 @default.
• W2100791732 crossrefType "journal-article" @default.
• W2100791732 hasAuthorship W2100791732A5042408270 @default.
• W2100791732 hasAuthorship W2100791732A5045519884 @default.
• W2100791732 hasAuthorship W2100791732A5060092467 @default.
• W2100791732 hasAuthorship W2100791732A5060734176 @default.
• W2100791732 hasAuthorship W2100791732A5064805536 @default.
• W2100791732 hasAuthorship W2100791732A5065617907 @default.
• W2100791732 hasAuthorship W2100791732A5080756848 @default.
• W2100791732 hasBestOaLocation W21007917321 @default.
• W2100791732 hasConcept C126322002 @default.
• W2100791732 hasConcept C127413603 @default.
• W2100791732 hasConcept C177713679 @default.
• W2100791732 hasConcept C194828623 @default.
• W2100791732 hasConcept C2776301958 @default.
• W2100791732 hasConcept C2778661090 @default.
• W2100791732 hasConcept C2778810321 @default.
• W2100791732 hasConcept C2779161974 @default.
• W2100791732 hasConcept C2780638905 @default.
• W2100791732 hasConcept C2780645631 @default.
• W2100791732 hasConcept C71924100 @default.
• W2100791732 hasConcept C78519656 @default.
• W2100791732 hasConceptScore W2100791732C126322002 @default.
• W2100791732 hasConceptScore W2100791732C127413603 @default.
• W2100791732 hasConceptScore W2100791732C177713679 @default.
• W2100791732 hasConceptScore W2100791732C194828623 @default.
• W2100791732 hasConceptScore W2100791732C2776301958 @default.
• W2100791732 hasConceptScore W2100791732C2778661090 @default.
• W2100791732 hasConceptScore W2100791732C2778810321 @default.
• W2100791732 hasConceptScore W2100791732C2779161974 @default.
• W2100791732 hasConceptScore W2100791732C2780638905 @default.
• W2100791732 hasConceptScore W2100791732C2780645631 @default.
• W2100791732 hasConceptScore W2100791732C71924100 @default.
• W2100791732 hasConceptScore W2100791732C78519656 @default.
• W2100791732 hasIssue "7" @default.
• W2100791732 hasLocation W21007917321 @default.
• W2100791732 hasOpenAccess W2100791732 @default.
• W2100791732 hasPrimaryLocation W21007917321 @default.
• W2100791732 hasRelatedWork W1972269502 @default.
• W2100791732 hasRelatedWork W1993190469 @default.
• W2100791732 hasRelatedWork W2006773714 @default.
• W2100791732 hasRelatedWork W2013904527 @default.
• W2100791732 hasRelatedWork W2021252689 @default.
• W2100791732 hasRelatedWork W2039688335 @default.
• W2100791732 hasRelatedWork W2896204226 @default.
• W2100791732 hasRelatedWork W2979702411 @default.
• W2100791732 hasRelatedWork W2990629389 @default.
• W2100791732 hasRelatedWork W3016213733 @default.
• W2100791732 hasVolume "16" @default.
• W2100791732 isParatext "false" @default.
• W2100791732 isRetracted "false" @default.
• W2100791732 magId "2100791732" @default.
• W2100791732 workType "article" @default.